Applications for new human medicines under evaluation - Oct 2016

This document lists information on applications for centralised marketing authorisation for human

medicines that the European Medicines Agency has received for evaluation. It includes the international

non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation

by the Committee for Medicinal Products for Human Use (CHMP). For generic and biosimilar medicines,

it includes the INN (active moiety only, with no information on salt, ester or derivative) and

therapeutic area.

This list only includes information for medicines whose applications have been validated at the time the

report was compiled. The information in this report was compiled on 4 October 2016.

Click on this link for more information.